Risperdal approval, "complete response" & revised warnings
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryJanssen Risperdal M-Tab launch begins during second week of May, following FDA approval of the fast-dissolving formulation of risperidone April 2. The company claims that the orally disintegrating tablets will boost compliance. Janssen began an advertising campaign stressing compliance in the fall. Janssen also is highlighting a compliance benefit for its sustained-release formulation of the atypical antipsychotic, Risperdal Consta. The firm filed a "complete response" for Risperdal Consta April 28, suggesting an October user fee goal. The product was deemed "not approvable" due to preclinical toxicology issues June 28, 2002. Janssen sent a "Dear Healthcare Provider" letter April 16 on updated safety labeling for Risperdal. A new warning on the risk of stroke notes cerebrovascular adverse events in risperidone trials of elderly patients with dementia-related psychosi
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.